This is a developing story. Please check back for updates. | After a tumultuous tenure marked by recent clashes with the ...

Flagship Pioneering-backed Alltrna is once again laying off staff, this time reducing its workforce by 19 people. | Flagship ...

In a strikingly blunt briefing, a senior FDA official accused uniQure of pushing “distorted” data to mask a “failed” therapy ...

After its latest pipeline clear-out, Merck KGaA is no longer pursuing any clinical-stage cancer candidates obtained through ...

The FDA will end a roughly nine-month hiatus of drug-related advisory committee meetings, with plans to convene its first ...

Zealand Pharma’s Roche-partnered amylin analog demonstrated “placebo-like tolerability” and up to 10.7% mean weight loss at ...

Two weeks after Teva touted promising long-term data for its Sanofi-partnered bowel disease drug, the Israeli pharma ...

Venture capital firm Portal Innovations is planning to open a 30,000-square-foot science incubator in Salt Lake City while ...

United Therapeutics has linked a once-daily drug candidate to a 55% drop in the risk of clinical worsening in a phase 3 trial ...

With colon cancer deaths rising among younger adults and millions of eligible Americans skipping their colonoscopies, ...

T-cell engager (TCE) specialist Candid Therapeutics has entered into a reverse merger agreement with Rallybio that will allow ...

The FDA has liberated the second of two Intellia Therapeutics clinical trials that were put on hold last October following a ...